Study of BMS-986504 for recurrent brain tumor
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of brain cancer called glioblastoma that has come back after initial treatment.
- You had surgery to remove as much of the tumor as possible (biopsy was okay if surgery wasn't safe) and radiation therapy.
- Your previous chemotherapy side effects have mostly gone away (except for hair loss or some nerve issues).
- You are 18 years old or older.
- You have a good level of daily function (able to care for yourself).
- You have healthy bone marrow, liver, and kidney function, as shown by blood tests.
- You can swallow pills without crushing or chewing them.
- You agree to use effective birth control if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.
This early-stage trial tests an experimental drug (BGB-58067) for people with a newly diagnosed glioblastoma that has a specific gene deletion (MTAP). It aims to see if the drug can shrink the tumor or slow its growth.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This trial tests a new drug, MT027, for people with high-grade glioma (a type of brain tumor) that has come back or continued to grow after standard treatment. The drug targets a protein called B7-H3 found on tumor cells. The goal is to see if it can help shrink tumors or slow the disease.
Hear when a new Glioblastoma WHO Grade IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.